PolarityTE Inc.

PolarityTE — Investor Presentation (March 2022)

34 slides from PolarityTE's investor presentation, Mar 10, 2022

  1. Slide 1: PolarityTE Investor Presentation

    Pol ari ityTE Investor Presentation Where Self Regenerates Self” March 2022

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties and investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Forward-looking stat

  3. Slide 3: Our Mission: Transforming the lives of patients

    Our Mission: Transforming the lives of patients... —Devon, Chronic Wound —Diane, Skin Cancer Survivor and —Natasha, Burn Survivor and SkinTE® Patient SkinTE® Patient SkinTE® Patient Tin

  4. Slide 4: Challenges in Wound Care

    Challenges in Wound Care Problem Market Existing Solutions a ~8.2m Medicare beneficiaries had wounds with or without infection in 2018" Medicare cost estimates for acute and chronic wound treatments ranged from $28.1 billion to $96.8 billion’ Common treatments such as split-thickness skin grafting h

  5. Slide 5: PolarityTE Highlights

    PolarityTE Highlights Building the Foundation Data Driven Patented

  6. Slide 6: Gaining Value Through the BLA Pathway

    Gaining Value Through the BLA Pathway Transition from a 361 HCT/P to a 351 HCT/P: * — SkinTE initially registered as a human cell, tissue, and cellular and tissue-based product regulated solely under Section 361 of the Public Health Service Act (PHS Act) and 21 CFR Part 1271 (i.e, as a 361 HCT/P) +

  7. Slide 7: SkinTE Positioned to Expand Access and Care

    SkinTE Positioned to Expand Access and Care SkinTE Chronic Cutaneous Wounds: + Diabetic Foot Ulcers ¢ Pressure Injuries ¢ Venous Leg Ulcers a ; ; : Traumatic Injuries — Burns (Acute and : Reconstruction) Necrotizing Fasciitis Surgical Reconstruction Skin Cancer Reconstruction Targeted Indications Pr

  8. Slide 8: Leveraging Pre-BLA Commercial Experience

    Leveraging Pre-BLA Commercial Experience (@Polarity[E’ Where Self Regenerates Self” a, Learned From Refined Demonstrated Developed Real Impacted Our Positioning in Commercial World Evidence _ Patients’ Lives Experience Complex Viability Wounds >1 year growth in Informed Over 1,200 SkinTE Advanced [D

  9. Slide 9: Our SkinTE Technology: A Novel and Differentiated Approach

    Our SkinTE Technology: PolaityTE A Novel and Differentiated Approach SD icestigndnss Technological Characteristics Autologous Personalized product that utilizes the patient's —— Tissue own viable tissue and cells Stem Cell Pathways Autologous multicellular segments include cellular populations found

  10. Slide 10: Complex Tissue Regeneration — From the Bench to the Bedside

    Complex Tissue Regeneration — PoartylE" From the Bench to the Bedside ve Sag Development of in-house animal* wound models and tissue analysis to unlock regenerative potential KRT14/ /TGM1/ Understanding skin’s complex regenerative cellular biology Complex technology requires advanced R&D *Animal mod

  11. Slide 11: Complex Tissue Regeneration — From the Bench to the Bedside (Continued)

    Complex Tissue Regeneration — Polarit ye From the Bench to the Bedside (Continued) Whe ere SkinTE is a full-thickness regenerative skin construct—not a skin substitute (B) Patient biopsy from a wound treated with SkinTE with demonstration of Harnessing skin's regenerative potential epidermis, dermis

  12. Slide 12: SkinTE Process Logistics

    SkinTE Process Logistics — Anticipated based on prior clinical experience E Harvest Box Fg Full-Thickness Skin Harvested S- ij Skin Harvest Sent to Manufacturing i in Self-Cooling Container : oe *Harvest size and location may vary Os SkinTE Returned to Facility/Provider SkinTE 3 © 2022 PolarityTE, I

  13. Slide 13: SkinTE — A Different Approach and Unique Product Characteristics

    SkinTE — A Different Approach and — Unique Product Characteristics Unique nature of clinical attributes with SkinTE has the potential to create a new approach for acute and chronic full-thickness wounds « Autologous, cell based Alternative Treatments Skin Substitutes, Best in Superficial Wounds, ¢ N

  14. Slide 14: Peer Reviewed Publications

    Peer Reviewed Publications 10. ai. 12. “A multicentre, randomised controlled clinical trial evaluating the effects of a novel autologous, heterogeneous skin construct in the treatment of Wagner one diabetic foot ulcers: Interim analysis” in International Wound Journal “Autologous Heterogeneous Skin

  15. Slide 15: Product Portfolio and Pipeline

    Product Portfolio and Pipeline Development Status Indication / Application Proof of Concept Pre-IND Submission IND Acceptance Trial Enrolling SkinTE used in over 1,200 clinical cases under the 361 HCT/P Pathway Chronic Cutaneous Wounds: Diabetic Foot Ulcers, Venous Leg . a Ulcers, Post-Surgical Chro

  16. Slide 16: SkinTE for Diabetic Foot Ulcers Represents a Significant Commercial Opportunity

    SkinTE for Diabetic Foot Ulcers Represents a Significant Commercial Opportunity 34m Lifetime incidence of diabetes expected to Diabetics in the United States* continue to increase in both the US and globally® DFUs expected to increase in parallel? 16

  17. Slide 17: Diabetic Foot Ulcers: Patient Impact

    Diabetic Foot Ulcers: Patient Impact “Five-year mortality and direct costs of care for people with diabetic foot ulcer complications are comparable to cancer” - Armstrong et al? Of moderate/severe DFUs lead to some \ level of ~40% \\_amputation'®."3 Of healed ulcers recur in 1 year’? 56.6% 5 Year mo

  18. Slide 18: SkinTE for Diabetic Foot Ulcers

    SkinTE for Diabetic Foot Ulcers Success in closing DFUs in Initial wound 9 weeks ater single Til wou Ze weeksatsr . . application of Skin single application randomized controlled trial and Ppteavon sere ee real-world evidence? !2 SkinTE in Full-Thickness DFUs a A Initial wound ~17 weeks after initia

  19. Slide 19: Non-IND Randomized Controlled Trial in DFUs

    PolarityTE” ‘Where Self Regenerates Self” Non-IND Randomized Controlled Trial in DFUs — Prospective, multi-center, randomized controlled trial evaluating SkinTE (AHSC) plus standard of care (SOC) vs. SOC alone in the treatment of DFUs Patient Signs Inclusion Criteria: Informed Consent = Wagner 1 DFU

  20. Slide 20: Non-IND Randomized Controlled Trial in DFUs

    Non-IND Randomized Controlled Trial in DFUs @ reer | 100 patients: 50 AHSC + SOC, 50 SOC were enrolled across 13 sites End of Study Visit Closure Confirmation Visit at 2 Weeks Ulcer Closed or Received 12 Weekly Visits? Not Closed Subject Continues Study End of Study Visit Primary Outcome Measure = P

  21. Slide 21: Greater Wound Closure with AHSC (DFU trial)

    Greater ¥ PAR with ™@ Application AHSC i of AHSC Primary Endpoint Secondary Endpoint Number of Applications Closure at 12 Weeks Increased Percent Area Reduction Applications of SkinTE (PAR) at 4, 6, 8, 10 and 12 Weeks AHSC: 35/50 (70%) Closed 1 Application: 45/50 (90%) p=0.009 SOC: 17/50 (34%) Close

  22. Slide 22: Greater Wound Closure with AHSC (VLU trial)

    Greater ¥ PAR with ™@ Application AHSC i of AHSC Primary Endpoint Secondary Endpoint Number of Applications Closure at 12 Weeks Increased Percent Area Reduction Applications of SkinTE (PAR) at 4, 6, 8, 10 and 12 Weeks AHSC: 10/14 (71%) Closed 1 Application: 13/14 (93%) p=0.000035 SOc: 5/15 (33%) Clo

  23. Slide 23: SkinTE for Pressure Injury Represents a Significant Commercial Opportunity

    SkinTE for Pressure Injury Represents @ a Significant Commercial Opportunity 2.5m Hospital acquired e reese A ts for 45% of -_ pressure injuries (HAPIs) — Affected Patient in the US per year" are the most common deaths secondary to 9.3% of Acute Care Patients'® hospital acquired hospital acquired co

  24. Slide 24: Pressure Injury Patient and Cost Burden

    Pressure Injury Patient and Cost Burden Stage III/IV pressure injuries account for 73% of all recurrence and 59% of the total Pl cost to the system!22° $26.8B Estimated annual cost of HAPI to the system2° Average length of stay for patients with PI vs 5 days for all other conditions'” $43,180 The co

  25. Slide 25: SkinTE for Pressure Injury

    SkinTE for Pressure Injury Real world evidence supports Residual Limb Pressure Injury22 proof of concept in pressure | injury?223 Only 50% of stage Ill ulcers and 30% of stage IV ulcers heal Initial wound ~11 weeks after single ~23 weeks after single ope . application of SkinTE application of SkinTE

  26. Slide 26: SkinTE for Acute Trauma — Advantageous Position

    SkinTE for Acute Trauma — Advantageous Pos SkinTE has been successfully deployed in clinical use for acute traumatic wounds ~84K Trauma cases per year?® This patient cohort is admitted to the hospital with open Lh >=: wounds as a primary diagnosis Using tibial type III fractures as a proxy, the woun

  27. Slide 27: SkinTE for Burns

    SkinTE for Burns ~42K Burn Cases Per year applicable for SkinTE?2 ~20% of these patients are recording Total Burn Surface areas (TBSA) of 10% or greater of their entire bodies, which emphasizes the need for alternatives to traditional STSG Standard of Care SkinTE in Acute Burn Initial wound © 2022 P

  28. Slide 28: De-Risked Asset Driving Near and Long-Term Growth

    De-Risked Asset Driving ® Near and Long-Term Growth Phase 3 IND Approved January 2022 g First pivotal trial expected to enroll in early Q2 2022 Scientific Body of Evidence g DFU and VLU RCTs totaling 129 patients met primary and secondary endpoints 2 > 10 peer-reviewed SkinTE scientific publications

  29. Slide 29: Key Financial Information

    Key Financial Information @ rere Cash and Cash Equivalents: ~$27.35 million as of September 30, 2021 Shares Outstanding: 82,948,751 as of February 11, 2022 Warrants Outstanding: 19,314,143 as of September 30, 2021 - Focused on Capital Efficiency

  30. Slide 30: Management Team with Deep Operational, Clinical, and R&D Experience

    Management Team with Deep Operational, Clinical, _— ; PolarityTE and Research and Development Experience West ones Management Team Nikolai Sopko, MD, PhD MS) Richard Hague Jacob Patterson Chief Executive Officer & Chief Financial Officer Chief Scientific Officer & | President \ Vice President R&D A

  31. Slide 31: Board of Directors

    Board of Directors Peter Cohen, MBA Chairman of the Board & Chairman of Compensation Committee + Former Board Member of the NYSE + Former Chairman of Shearzon Lehman Hutton, Inc. + Vice Chairman and Lead Director of the Board of Directors of Scientific Games Corporation + Federal Reserve Intemationa

  32. Slide 32: PolarityTE

    Polarit Ly Where Self Regenerates SF

  33. Slide 33: References

    References @ rosie [ Sen, Chandan K. “Human Wounds and Its Burden: An Updated Compendium of Estimates.” Advances in wound care vol. 8,2 (2019): 39-48. doi:10.1089/wound.2019.0946 Armstrong, David G et al. “Complete wound closure following a single topical application of a novel autologous homologous

  34. Slide 34: References (Continued)

    References (Continued) @ rosie 18. 19. 20. 21: 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33), 34. VanGilder C, Macfarlane GD, Meyer S. Results of nine international pressure ulcer prevalence surveys: 1989 to 2005. Ostomy Wound Manage. 2008;54(2):40-54. Bates-Jensen BM, Guihan M, Garber SL, Chin AS

PolarityTE — Investor Presentation (March 2022) on 6ix